Efficacy and Safety of Tazarotene Gel in Nail Psoriasis

Almirall

Status and phase

Completed

Phase 2

Conditions

Nail Psoriasis

Treatments

Drug: Experimental Tazarotene Gel

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

H 573 000 1307

2013-004519-28 (EudraCT Number)

Details and patient eligibility

About

The aim of this study is to determine the efficacy and safety of topical application of the gel compared to placebo in nail psoriasis.

Enrollment

66 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Exclusion criteria

Key exclusion criteria:

any other skin condition, with a potential to affect the nails or to interfere with evaluation of the disease;
history of hypersensitivity to retinoids or to other components of the trial medication
topical treatment of nails with antipsoriatics in the 4 weeks preceding the treatment phase;
systemic treatment of psoriasis within the three months before the treatment phase of the trial or during the trial
intralesional steroid injection before the treatment phase of the trial
phototherapy before the treatment phase of the trial;
any chronic infection or condition capable of interfering with the conduct of the trial;
evidence of drug or alcohol abuse;
symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks preceding the treatment phase of the trial;
participation in another clinical trial within the last 4 weeks prior to first treatment in this clinical trial;
pregnancy or nursing;